Antifibrotics for Chronic Hepatitis C

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 365-373

  Pockros, Paul J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antifibrotics; Caspase inhibitors; Hepatitis C virus; Interferon gamma 1b; Long term pegylated interferons

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALPHA INTERFERON; ANTIFIBROTIC AGENT; CASPASE INHIBITOR; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ESTRADIOL; FARNESOID X RECEPTOR AGONIST; GAMMA INTERFERON; GAMMA1B INTERFERON; GLYCYRRHIZIC ACID; HALOFUGINONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; OCTREOTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PROSTAGLANDIN E2; QUERCETIN; RAPAMYCIN; RETINOIC ACID; SILYMARIN; SOLUBLE PLATELET DERIVED GROWTH FACTOR ANTAGONIST; SOLUBLE TYPE II FUSION MOLECULE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; FIBROSING ALVEOLITIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; LIVER BIOPSY; LIVER FIBROSIS; LOW DRUG DOSE; NONHUMAN; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CASPASES; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-GAMMA; LIVER CIRRHOSIS; PENTANOIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 67650555649     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.005     Document Type: Review

References (30)

1. Friedman S.L. Evaluation of fibrosis and hepatitis C. Am J Med 107 6B (1999) 27S-30S
2. Nakamura T., Sakata R., Ueno T., et al. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 32 2 (2000) 247-255
3. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 19 (1994) 1286-1292
4. Ulloa L., Doody J., and Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397 6721 (1999) 710-713
5. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
6. Ziesche R., Hofbauer E., Wittmann K., et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 17 (1999) 1264-1269
7. Saez-Royuela F., Porres J.C., Moreno A., et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 13 2 (1991) 327-331
8. Pockros P.J., Jeffers L., Afdhal N., et al. Final results of a double-blind, placebo-controlled trial of the anti-fibrotic efficacy of interferon-gamma 1b in chronic hepatitis C with advanced fibrosis or cirrhosis. Hepatology 45 3 (2007) 569-578
9. Muir A.J., Sylvestre P.B., and Rockey D.C. Interferon gamma-1 for the treatment of chronic hepatitis C infection. [abstract]. Gastroenterology 124 Suppl 1 (2003) A 718
10. Soza A., Heller T., Ghany M., et al. Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 43 1 (2005) 67-71
11. Di Bisceglie A.M., Rustgi A.K., Kassianides C., et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 11 2 (1990) 266-270
12. Kakumu S., Ishikawa T., Mizokami M., et al. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J Med Virol 35 1 (1991) 32-37
13. Weng H.L., Wang B.E., Jia J.D., et al. Effect of interferon gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 3 8 (2005) 819-828
14. Goodman Z.D., Becker R.L., Pockros P.J., et al. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology 45 4 (2007) 886-894
15. McHutchison J.G., Poynard T., Afdhal N., et al. Fibrosis as an end point for clinical trials in liver disease: a consensus report of the International Fibrosis Group. Clin Gastroenterol Hepatol 4 10 (2006) 1214-1220
16. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 23 (2008) 2429-2441
17. Poynard T., Schiff E., Terg R., et al. High early viral response (EVR) with PEG-Intron/Rebetol (PR) weight based dosing (WBD) in previous interferon/ribavirin HCV treatment failures; early results of the EPIC3 trial. [abstract]. Hepatology 40 Suppl 1 (2004) 238A
18. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136 5 (2009) 1618-1628
19. Afdhal N.H., Levine R., Brown Jr. R., et al. Colchicine versus peg-interferon alfa 2B long term therapy: results of the 4 year copilot trial. [abstract]. J Hepatol 48 Suppl 2 (2008) S4
20. Afdhal N., Frelich B., Levine R., et al. Colchicine versus PEG-Intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. [abstract]. Hepatology 40 (2004) 239A
21. Shiffman M.L., Morishima C., Lindsay K.L., et al. Suppression of serum HCV RNA levels during maintenance peginterferon (PEG-IFN) alfa-2a therapy and clinical outcomes in the HALT-C trial. [abstract]. J Hepatol 48 Suppl 2 (2008) S62
22. Guicciardi M.E., and Gores G.J. Apoptosis: a mechanism of acute and chronic liver injury. Gut 54 7 (2005) 1024-1033
23. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 2 (2005) 209-218
24. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 2 (2004) 273-278
25. Bantel H., Lugering A., Poremba C., et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34 4 Pt 1 (2001) 758-767
26. Pianko S., Patella S., Ostapowicz G., et al. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 8 6 (2001) 406-413
27. Hoglen N.C., Chen L.S., Fisher C.D., et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 309 2 (2004) 634-640
28. Canbay A., Feldstein A., Baskin-Bey E., et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308 3 (2004) 1191-1196
29. Pockros P.J., Schiff E.R., Shiffman M.L., et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, lowers aminotransferases in patients with chronic hepatitis C. Hepatology 46 2 (2007) 324-329
30. Available at:. ClinicalTrials.gov Identifier: NCT00725803. Accessed March 6, 2009